Obtenga las últimas noticias sobre las acciones de Biomea Fusion con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de BMEA

Últimas noticias sobre

BIOMEA FUSION INC

Biomea Fusion

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Biomea Fusion Inc

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Cet analyste en technologie atypique commence la couverture sur une note haussière; voici les 5 meilleures initiations pour jeudi

Dieser eigenartige Technologie-Analyst beginnt die Berichterstattung mit einer optimistischen Note; Hier sind die Top 5 Initiativen für Donnerstag

这位奇特的科技分析师以看涨的态度开始覆盖；以下是周四的前5个启动。

この奇妙なテックアナリストが楽観的なノートでカバレッジを開始します。こちらが木曜日のトップ5のイニシエーションです。

Questo analista tecnologico inusuale inizia la copertura con una nota rialzista; Ecco le prime 5 iniziative per giovedì

هذا المحلل التقني غير المألوف يبدأ التغطية بتوصية إيجابية؛ إليك أعلى 5 بدءات ليوم الخميس

Este analista de tecnología comienza la cobertura de una manera peculiar con una nota optimista; Aquí están las 5 principales iniciativas para el jueves

이 기이한 기술 분석가가 강세로 커버리지를 시작합니다; 목요일을 위한 상위 5개 시작 주식입니다.

Five Below upgraded, Bill downgraded: Wall Street's top analyst calls

BILL

BMEA

CRWV

FIVE

GPRE

GUTS

SLGN

TTAN

WYNN

Alpha Cognition

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Avalo Therapeutics

Compugen

Coya Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Elutia

Fate Therapeutics

HilleVax

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Macrogenics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Oncolytics Biotech

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Skye Bioscience

Spero Therapeutics

Surrozen

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TScan Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Jefferies

Citigroup

Scotiabank

D. Boral Capital

Piper Sandler

Comments

Biomea Fusion Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL